This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans
by Zacks Equity Research
CYTK reports a wider-than-expected Q4 loss as expenses rise, but Myqorzo wins FDA nod and global expansion advances, with $1.22B cash fueling 2026 catalysts.
SNYPositive Net Change BMYNegative Net Change BAYRYPositive Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
by Zacks Equity Research
Recursion Pharmaceuticals stock up on narrower Q4 loss as revenues jump on Roche milestone, beating estimates and boosting cash runway into 2028.
CSTLPositive Net Change HRMYPositive Net Change IMCRNegative Net Change RXRXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Costco Wholesale, Roche, Lam Research, Spruce Power and IDT
by Zacks Equity Research
Costco, Roche and Lam Research lead Zacks??? top stock reports, with standout gains and resilient fundamentals across sectors.
RHHBYNegative Net Change LRCXPositive Net Change COSTNegative Net Change IDTPositive Net Change SPRUPositive Net Change
computers pharmaceuticals retail semiconductor utilities
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
by Zacks Equity Research
APLS posts wider-than-expected Q4 loss as Syfovre sales slip 8%, but revenues top estimates and Empaveli surges 50% on a strong new indication launch.
APLSNegative Net Change CSTLPositive Net Change HRMYPositive Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Can J&J Sustain Its Double-Digit Oncology Growth Streak?
by Kinjel Shah
JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?
AZNNegative Net Change JNJNegative Net Change PFENegative Net Change MRKNegative Net Change
pharmaceuticals
Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?
by Kinjel Shah
LLY's Mounjaro and Zepbound drove 56% of revenues in 2025 as obesity demand surged, with new launches and Medicare access set to fuel growth.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
pharmaceuticals
Top Stock Reports for Costco, Roche & Lam Research
by Mark Vickery
Costco's resilient membership model, strong cash flow and e-commerce momentum position it to weather market turmoil and keep earnings growing.
RHHBYNegative Net Change GRMNNegative Net Change SYKPositive Net Change LRCXPositive Net Change EQTPositive Net Change COSTNegative Net Change IDTPositive Net Change SPRUPositive Net Change
computers pharmaceuticals retail semiconductor utilities
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel
by Zacks Equity Research
Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.
BMYNegative Net Change GILDNegative Net Change ACLXPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026
by Kinjel Shah
LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
pharmaceuticals
IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?
by Sundeep Ganoria
With Amtagvi sales surging but shares down 46%, can Iovance's growth runway outshine Rigel's strong 2025 rally?
SNYPositive Net Change LLYNegative Net Change RIGLNegative Net Change IOVAPositive Net Change
biotechs medical pharmaceuticals